CareCloud(CCLD)

Search documents
CareCloud to Announce First Quarter 2025 Results on May 6, 2025
GlobeNewswire· 2025-04-17 12:00
SOMERSET, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, will release its financial results for the first quarter ended March 31, 2025 before the market opens on Tuesday, May 6, 2025. The Company will follow with a conference call for investors at 8:30 a.m. Eastern Time. The live webcast of the conference call and related presentation slides can be accessed at i ...
CareCloud to Present at the LD Micro Invitational XV
Newsfilter· 2025-04-07 12:00
SOMERSET, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the "Company") (NASDAQ:CCLD, CCLDO)), a leading provider of practice management, healthcare technology and AI-driven solutions to medical practices across the country, is pleased to announce its participation in the 15th Annual LD Micro Invitational at the Westin Grand Central Hotel in New York on April 9-10, 2025. The Company is scheduled to present on April 10, 2025 at 3:30 p.m. ET. CareCloud's management team will deliver a corporate pre ...
CareCloud Acquires RevNu Medical Management, Completing Second Acquisition in 31 Days
GlobeNewswire· 2025-04-02 13:00
SOMERSET, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the “Company”) (Nasdaq: CCLD, CCLDO), a leading provider of practice management, healthcare technology and AI-driven solutions to medical practices across the country, today announced the acquisition of RevNu Medical Management (“RevNu”), an emerging audiology-focused revenue cycle management (“RCM”) company based in Westminster, California. “We’ve spent years building trusted relationships within the audiology community, and we couldn’t be ...
Alpine ENT Expands Partnership with CareCloud, Implements FrontDesk Assist to Enhance Patient Experience
Newsfilter· 2025-03-26 11:00
Core Insights - CareCloud, Inc. has expanded its services with Alpine Ear, Nose & Throat PC, implementing the FrontDesk Assist solution to enhance operational efficiency and patient satisfaction [1][4] - The partnership aims to streamline front-office operations, resulting in shorter patient wait times and improved appointment scheduling [2][3] Company Overview - CareCloud is a provider of healthcare technology and AI-powered revenue cycle management solutions, serving over 40,000 providers [6] - The company focuses on increasing financial and operational performance while reducing administrative burdens for healthcare organizations [6] Product Details - FrontDesk Assist is designed to support critical front-office functions such as appointment scheduling, referral management, surgery estimates, and prior authorizations [2][4] - The solution is now available nationwide to healthcare practices across various specialties, complementing CareCloud's existing EHR and RCM platforms [4]
CareCloud Announces Preferred Stock Dividend Payments
Newsfilter· 2025-03-14 11:00
SOMERSET, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (the "Company") (NASDAQ:CCLD, CCLDO, CCLDP)), a leader in healthcare technology and generative AI solutions for medical practices and health systems nationwide, announced today that its Board of Directors (the "Board") has declared monthly cash dividends for its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock ("Series A Preferred Stock") and its 8.75% Series B Cumulative Redeemable Perpetual Preferred Stock ("Series B Preferre ...
CareCloud(CCLD) - 2024 Q4 - Annual Report
2025-03-13 20:30
Financial Performance - The company reported net revenue of $110.837 million for the year ended December 31, 2024, a decrease of 5.2% from $117.059 million in 2023[261] - Adjusted EBITDA for 2024 was $24.057 million, significantly up from $15.429 million in 2023, representing a year-over-year increase of 55.5%[261] - The company achieved a GAAP net income of $7.851 million in 2024, compared to a net loss of $48.674 million in 2023[261] - Adjusted operating income for 2024 was $11.455 million, up from $5.967 million in 2023, resulting in an adjusted operating margin of 10.3% compared to 5.1% in the previous year[264] - Non-GAAP adjusted net income for 2024 was $10.520 million, compared to $4.801 million in 2023, indicating a substantial improvement in profitability[264] - The company reported a non-GAAP adjusted earnings per share of $0.65 for 2024, an increase from $0.30 in 2023[266] - The company’s GAAP operating margin improved to 8.2% in 2024 from a negative 40.2% in 2023[264] - Operating income for 2024 was $9,121,000, compared to an operating loss of $47,115,000 in 2023[267] - Net income for 2024 was $7,851,000, a significant improvement from a net loss of $48,674,000 in 2023[267] - Net income attributable to common shareholders was a loss of $4,459,000 in 2024, an improvement from a loss of $64,348,000 in 2023[267] Expenses and Cost Management - The company’s offshore operations accounted for approximately 15% of total expenses in 2024, up from 9% in 2023, with personnel-related costs making up about 75% of these expenses[256] - Total operating expenses decreased to $101,716,000 in 2024 from $164,174,000 in 2023, reflecting a reduction of 38%[267] - Direct operating costs represented about 13% of total costs in 2024, compared to 11% in 2023, indicating a slight increase in operational efficiency[282] - General and administrative expenses accounted for approximately 22% of total expenses in 2024, up from 17% in 2023, suggesting increased administrative costs[284] - Selling and marketing expenses decreased by $3.4 million or 35% to $6.2 million in 2024 from $9.7 million in 2023[314] - General and administrative expenses decreased by $5.3 million or 25% to $16.1 million in 2024 from $21.5 million in 2023[315] - Research and development expenses decreased by $955,000 or 20% to $3.8 million in 2024 from $4.7 million in 2023[316] - Total operating expenses for 2024 were $101.7 million, a decrease of $62.5 million or 38% from $164.2 million in 2023[313] Cash Flow and Financial Position - Cash balance increased to $5,145,000 in 2024 from $3,331,000 in 2023[268] - Positive cash flow from operations increased to $20.6 million in 2024 from $15.5 million in 2023, representing a 34% increase[331] - Cash used in investing activities decreased to $7.4 million in 2024 from $11.6 million in 2023, a reduction of $4.2 million[336] - Cash used in financing activities was $11.3 million in 2024, down from $13.3 million in 2023, including the full repayment of a $10 million credit line[337] - The company recorded a net increase in cash of $1.8 million in 2024, compared to a decrease of $8.9 million in 2023, marking a turnaround of $10.8 million[331] Client and Revenue Metrics - The company served approximately 40,000 providers across about 2,600 practices as of December 31, 2024, maintaining a stable client base[275] - Customer renewal rates improved to 95% in 2024 from 91% in 2023, reflecting strong client retention[276] - Revenue from technology-enabled business solutions accounted for approximately 67% of total revenues in 2024, up from 65% in 2023[277] - Revenue from technology-enabled business solutions was $73.7 million in 2024, down from $76.6 million in 2023[310] - Professional services revenue decreased by $4.8 million in 2024 compared to 2023, primarily due to the winding down of services for two large accounts[311] Goodwill and Impairment - Goodwill impairment charges in 2023 amounted to $42,000,000, reflecting a significant write-down related to the Healthcare IT reporting unit[287] - Goodwill impairment of approximately $2 million was recorded in October 2023, with an additional impairment of approximately $40 million recorded in December 2023[305] - Goodwill impairment charge of $42 million was recorded in 2023, resulting in the reversal of the entire deferred tax liability at December 31, 2023[325] Shareholder Information - The total fully diluted shares increased to 16,498,736 in 2024 from 16,614,000 in 2023[266] - The weighted average common shares outstanding increased to 16,146,975 in 2024 from 15,669,472 in 2023[267] - Shareholders' equity increased to $49,774,000 in 2024 from $41,717,000 in 2023[268] Tax and Interest - The income tax provision for 2024 was $160,000, contrasting with a tax benefit of $364,000 in 2023[323] - Interest income decreased by $66,000 or 43% to $88,000 for the year ended December 31, 2024, compared to $154,000 in 2023[320] - Interest expense decreased by $294,000 or 25% to $900,000 for the year ended December 31, 2024, from $1.2 million in 2023[321] - Other expense - net improved to $298,000 in 2024 from $883,000 in 2023, primarily due to a foreign exchange gain of $130,000 compared to a loss of $790,000 in 2023[322] Future Outlook - The company plans to continue leveraging its offshore operations to maintain competitive cost advantages in the healthcare IT sector[256] - The company expects to achieve further economies of scale as it grows, potentially reducing direct operating costs as a percentage of revenue[282] - The company has a total federal NOL carry forward of approximately $265 million, with $187 million expiring between 2031 and 2038[328]
CareCloud(CCLD) - 2024 Q4 - Earnings Call Transcript
2025-03-13 14:41
CareCloud, Inc. (NASDAQ:CCLD) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Kristen Rothe - Corporate Counsel Stephen Snyder - Co-Chief Executive Officer Hadi Chaudhry - Co-Chief Executive Officer & Director Norman Roth - Interim Chief Financial Officer & Corporate Controller Mahmud Haq - Founder & Executive Chairman Conference Call Participants Michael Kim - Zacks Small-Cap Research Jeffrey Cohen - Ladenburg Thalmann Allen Klee - Maxim Group Operator Greetings, and welcome ...
CareCloud(CCLD) - 2024 Q4 - Earnings Call Presentation
2025-03-13 12:19
Q4 2024 RESULTS Nasdaq Global Market: CCLD, CCLDP, CCLDO March 13, 2025 A leading provider of technology-enabled services and solutions that redefine the healthcare revenue cycle © CareCloud, Inc. 2025 Safe Harbor Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by term ...
CareCloud(CCLD) - 2024 Q4 - Annual Results
2025-03-13 11:05
Financial Performance - GAAP net income for full year 2024 was $7.9 million, a significant turnaround from a net loss of $48.7 million in 2023[5] - Adjusted EBITDA for full year 2024 increased by 56% to $24.1 million, up from $15.4 million in 2023[5] - Free cash flow for full year 2024 reached $13.2 million, representing a 244% increase from $3.8 million in 2023[5] - Fourth quarter 2024 GAAP net income was $3.3 million, compared to a net loss of $43.7 million in Q4 2023[8] - Adjusted EBITDA for Q4 2024 was $7.1 million, or 25% of revenue, up from $4.1 million in the same period last year[9] - Operating income for the year ended December 31, 2024, was $9,121, compared to a loss of $47,115 in 2023, indicating a significant turnaround[31] - Net income for the year ended December 31, 2024, was $7,851, compared to a net loss of $48,674 in 2023, reflecting improved financial performance[31] - GAAP net income for Q4 2024 was $3,296,000, a significant improvement compared to a loss of $43,692,000 in Q4 2023; for the year, net income was $7,851,000 compared to a loss of $48,674,000 in 2023[41] - Non-GAAP adjusted operating income for Q4 2024 was $3,940,000, up from $1,191,000 in Q4 2023, with a non-GAAP adjusted operating margin of 14.0% compared to 4.2% in the same quarter last year[39] - Non-GAAP adjusted net income for Q4 2024 was $3,871,000, compared to $835,000 in Q4 2023, resulting in a non-GAAP adjusted net income per share of $0.24 versus $0.05[41] Revenue and Cash Flow - Revenue for full year 2024 was $110.8 million, a decrease from $117.1 million in 2023[6] - Total net revenue for the year ended December 31, 2024, was $110,837, a decrease of 5.2% from $117,059 in 2023[31] - Net revenue for Q4 2024 was $28,239,000, a slight decrease from $28,416,000 in Q4 2023, while total revenue for the year decreased from $117,059,000 in 2023 to $110,837,000 in 2024[39] - Free cash flow for Q4 2024 was $2,967,000, an increase from $1,449,000 in Q4 2023, while annual free cash flow rose to $13,236,000 from $3,848,000[45] - Cash at the end of the year increased to $5,145 from $3,331, marking a 54.4% increase[33] - Net cash provided by operating activities for Q4 2024 was $5,229,000, up from $3,740,000 in Q4 2023[45] Cost Management and Liabilities - Total operating expenses for the year decreased to $101,716 in 2024 from $164,174 in 2023, a reduction of 38.0%[31] - Total liabilities decreased significantly to $21,840 in 2024 from $36,109 in 2023, a reduction of 39.4%[29] - The company’s accumulated deficit improved to $(66,630) in 2024 from $(74,481) in 2023, showing a reduction of 10.4%[29] - The conversion of 3.5 million Series A Preferred Stock into common stock will reduce annual dividend burden by $7.7 million[5] - The company reported a preferred stock dividend of $12,310 for the year ended December 31, 2024, down from $15,674 in 2023[31] - The company incurred goodwill impairment charges of $42,000,000 in Q4 2023, which did not recur in Q4 2024[39] Future Projections - The company expects 2025 revenue to be between $111 million and $114 million, based on growth from existing clients and new acquisitions[15] - Adjusted EBITDA for 2025 is projected to be between $26 million and $28 million, reflecting cost reduction efforts[16] Shareholder Information - The total number of end-of-period shares increased to 16,256,236 in Q4 2024 from 15,880,092 in Q4 2023[41] Financial Metrics - Free cash flow is considered an important financial measure for evaluating the Company's performance[61] - Free cash flow does not account for payments required for debt service and other contractual obligations[61] - The Company views free cash flow as supplemental information to its condensed consolidated statements of cash flows[61]
CareCloud Reports Record Breaking Full Year 2024 Net Income
GlobeNewswire· 2025-03-13 11:00
Core Viewpoint - CareCloud, Inc. has achieved a significant turnaround in its financial performance for the year ended December 31, 2024, returning to GAAP profitability, generating record cash flow, resuming dividends, and strengthening its balance sheet [1][4][9] Financial Performance - Full year 2024 revenue was $110.8 million, down from $117.1 million in 2023 [4][6] - GAAP net income for 2024 was $7.9 million, a recovery from a net loss of $48.7 million in 2023 [4][6] - Adjusted net income for 2024 was $10.5 million, or $0.65 per share [4][8] - Adjusted EBITDA for 2024 was $24.1 million, an increase of 56% from $15.4 million in 2023 [6][9] Fourth Quarter Performance - Fourth quarter 2024 revenue was $28.2 million, slightly down from $28.4 million in Q4 2023 [5][6] - GAAP net income for Q4 2024 was $3.3 million, compared to a net loss of $43.7 million in Q4 2023 [6][7] - Adjusted EBITDA for Q4 2024 was $7.1 million, a 73% increase from $4.1 million in the same period last year [6][7] Operational Improvements - The company has successfully transformed its cost structure, enhancing operational efficiency through AI-driven innovations [2][4] - Free cash flow for 2024 was $13.2 million, a substantial increase of 244% from $3.8 million in 2023 [6][9] Shareholder Actions - In January 2025, CareCloud increased the number of authorized common shares from 35 million to 85 million and declared two months of Preferred Stock dividends [3] - The conversion of 3.5 million shares of Series A Preferred Stock into common stock resulted in the issuance of 26 million additional common shares, reducing the annual dividend burden by $7.7 million [3][6] 2025 Guidance - For the fiscal year ending December 31, 2025, CareCloud expects revenue between $111 million and $114 million [12][13] - Adjusted EBITDA is anticipated to be between $26 million and $28 million, with net income per share projected at $0.10 to $0.13 [12][13]